Insight Molecular Diagnostics Inc. IMDX
2.47 USD -0.03 (-1.20%)
At closeNov 10, 2026, 4:00 PM EST
2.47 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
2.37 Day range 2.58
2.35 52-week range 8.51
- YTD
- -67.07%
- 1 year
- -63.68%
News
defenseworld.net Aclaris Therapeutics (NASDAQ:ACRS) vs. Oncocyte (NASDAQ:IMDX) Financial Contrast Aclaris Therapeutics (NASDAQ: ACRS - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…
globenewswire.com iMDx to Release Third Quarter Results on November 16, 2026 NASHVILLE, Tenn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2026 financial results after the…
defenseworld.net Oncocyte (NASDAQ:IMDX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Analysis Oncocyte (NASDAQ: IMDX - Get Free Report) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ: LKFT - Get Free Report) are both healthcare companies, but which is the superior business?…
globenewswire.com iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch NASHVILLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced the appointment of Donnie Purto as Senior Vice President of Sales to lead the…
benzinga.com iMDx Amends Chronix Merger Agreement, Replacing Ongoing 10% CNI Monitor Royalty With 10% Sale Payment Upon CNI Monitor Sale As previously reported, Insight Molecular Diagnostics Inc. (the "Company" or "iMDx") entered into an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and
globenewswire.com iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual…
benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8 LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.
benzinga.com Transcript: Insight Molecular Q2 2026 Earnings Conference Call Insight Molecular (NASDAQ:IMDX) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings…
seekingalpha.com Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript- benzinga.com Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo,…
globenewswire.com Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday,…
seekingalpha.com Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
benzinga.com CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.500K Estimate Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 23.33 percent increase over losses of…
globenewswire.com iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the…
globenewswire.com iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection Serial monitoring of patients through donor-derived…
globenewswire.com Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for…
globenewswire.com IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of…
globenewswire.com iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant -Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-
globenewswire.com Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry,…
globenewswire.com IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone GraftAssure assay doubles reliability of…
seekingalpha.com Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript
globenewswire.com iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced it will be highlighting its GraftAssure™ technology at the upcoming…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Insight Molecular Q1 2026 Earnings Call Transcript 
seekingalpha.com Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript- benzinga.com Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 47.37 percent decrease over losses of…
globenewswire.com IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first…
benzinga.com Earnings Scheduled For May 13, 2026 
benzinga.com Alpha Buying: Insider Conviction in High-Risk Biotech - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Insight Molecular Diagnostics Files GraftAssureDx For Kidney Transplant Rejection Testing For FDA Review Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results.Submitted GraftAssureDx™ for kidney…
benzinga.com Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 13.92 percent. This is a 3.57 percent increase over losses of…- benzinga.com Earnings Scheduled For March 26, 2026
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Lake Street Maintains Buy on Insight Molecular, Raises Price Target to $12 Lake Street analyst Thomas Flaten maintains Insight Molecular (NASDAQ:IMDX) with a Buy and raises the price target from $8 to $12.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Insight Molecular Diagnostics Commences ~$26M Offering Of 4.526M Common Shares At $5.75/Share Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), ("iMDx" or the "Company"), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and…
benzinga.com Insight Molecular Outlines Commercial Gains, FDA De Novo Submission Plans For GraftAssureDx In 2026 GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx™ FDA IVD approval application 95% complete at- benzinga.com Needham Maintains Buy on Insight Molecular, Raises Price Target to $9 Needham analyst Mike Matson maintains Insight Molecular (NASDAQ:IMDX) with a Buy and raises the price target from $4.25 to $9.
- benzinga.com Insight Molecular Q3 EPS $(0.34) Misses $(0.21) Estimate, Sales $139.000K Miss $284.000K Estimate Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.21) by 60.38 percent. This is a 17.07 percent increase over losses of…
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com A Look at Insight Molecular's Upcoming Earnings Report
- benzinga.com Insight Molecular Diagnostics Publishes GraftAssure Study In AJT, Demonstrates Assay's Value In Monitoring High-Risk Kidney Transplant Patient American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to…
benzinga.com Insight Molecular Launches 5,000-Patient Registry To Advance Kidney Transplant Rejection Test Insight Molecular Diagnostics, Inc. (NASDAQ:IMDX), ("iMDx"), today announced a positive strategic update and novel registry that will serve to gather real-world data on patient experiences and…- benzinga.com Insight Molecular Diagnostics Enrolls Patients In Its Clinical Trial To Assess GraftAssureDx iMDx's ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026NASHVILLE,…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session